Phagenesis

About Phagenesis

Phagenesis is a pioneering biotechnology company based in the UK, dedicated to advancing therapeutic solutions for patients suffering from neurological disorders. Our core mission is to harness the power of phage therapy to develop innovative treatments that address unmet medical needs.

At Phagenesis, we focus on the research and development of phage-based therapies that target specific pathogens, offering a tailored approach to treatment. Our team of experienced scientists and researchers are committed to exploring the potential of bacteriophages as a viable alternative to traditional antibiotics, particularly in the face of rising antibiotic resistance.

We believe in a patient-centric approach, ensuring that our therapies not only meet regulatory standards but also improve the quality of life for those affected by chronic conditions. Our state-of-the-art facilities are equipped with cutting-edge technology, enabling us to conduct rigorous testing and validation of our products.

Phagenesis is also dedicated to collaboration, working closely with academic institutions and healthcare providers to foster innovation and share knowledge within the field. We aim to lead the way in phage therapy research, contributing to the global effort against infectious diseases.

As we look to the future, Phagenesis remains committed to expanding our portfolio of therapies and enhancing our understanding of phage biology. Our vision is to become a leader in the biopharmaceutical industry, providing effective and safe treatments that can transform patient care.

• Innovative Research: Focused on developing phage-based therapies.
• Patient-Centric Solutions: Committed to improving patient outcomes.
• Collaborative Approach: Partnering with leading institutions for research and development.

Join us on our journey to revolutionise the treatment of neurological disorders through the power of phage therapy.